VERICEL CORPORATION Proceeds from Common Stock Issued
VERICEL CORPORATION (VCEL) reported Proceeds from Common Stock Issued of $4.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfCommonStock · last filed 2026-07-30
- VERICEL CORPORATION proceeds from issuance of common stock for the quarter ending 2026-06-30 was $2.86M, a 59.84% increase year-over-year.
- VERICEL CORPORATION proceeds from issuance of common stock for the quarter ending 2026-03-31 was $1.56M, a 83.39% decline year-over-year.
- VERICEL CORPORATION proceeds from issuance of common stock for the quarter ending 2025-12-31 was $1.25M, a 82.72% decline year-over-year.
- VERICEL CORPORATION proceeds from issuance of common stock for the quarter ending 2025-09-30 was $1.48M, a 74.43% decline year-over-year.
- VERICEL CORPORATION proceeds from issuance of common stock for fiscal 2025 was $13.93M, a 43.16% decline from fiscal 2024.
- VERICEL CORPORATION proceeds from issuance of common stock for fiscal 2024 was $24.52M, a 308.60% increase from fiscal 2023.
- VERICEL CORPORATION proceeds from issuance of common stock for fiscal 2023 was $6.00M.
| Period end | Proceeds from Issuance of Common Stock | Proceeds from Issuance of Common Stock 3 month | Proceeds from Issuance of Common Stock 6 month | Proceeds from Issuance of Common Stock 9 month | Proceeds from Issuance of Common Stock 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $4.42M 10-Q · filed 2026-07-30 | $5.68M derived: sum of 3 quarters · filed 2026-07-30 | $7.16M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-07 | $2.82M derived: sum of 2 quarters · filed 2026-05-07 | $4.30M derived: sum of 3 quarters · filed 2026-05-07 | $6.09M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.74M derived: sum of 2 quarters · filed 2026-02-26 | $4.53M derived: sum of 3 quarters · filed 2026-07-30 | $13.93M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $3.27M derived: sum of 2 quarters · filed 2026-07-30 | $12.68M 10-Q · filed 2025-11-06 | $19.94M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-06-30 | $1.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $11.20M 10-Q · filed 2026-07-30 | $18.46M derived: sum of 3 quarters · filed 2026-07-30 | $24.25M derived: sum of 4 quarters · filed 2026-07-30 | |
| 2025-03-31 | $9.41M 10-Q · filed 2026-05-07 | $16.67M derived: sum of 2 quarters · filed 2026-05-07 | $22.46M derived: sum of 3 quarters · filed 2026-05-07 | $26.90M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $7.26M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.06M derived: sum of 2 quarters · filed 2026-02-26 | $17.49M derived: sum of 3 quarters · filed 2026-02-26 | $24.52M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $5.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $10.23M derived: sum of 2 quarters · filed 2025-11-06 | $17.25M 10-Q · filed 2025-11-06 | $18.64M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-06-30 | $4.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $11.46M 10-Q · filed 2025-07-31 | $12.85M derived: sum of 3 quarters · filed 2026-02-26 | $13.96M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2024-03-31 | $7.03M 10-Q · filed 2025-05-08 | $8.41M derived: sum of 2 quarters · filed 2026-02-26 | $9.53M derived: sum of 3 quarters · filed 2026-02-26 | $10.80M derived: sum of 4 quarters · filed 2026-02-26 | |
| 2023-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.50M derived: sum of 2 quarters · filed 2026-02-26 | $3.77M derived: sum of 3 quarters · filed 2026-02-26 | $6.00M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.39M derived: sum of 2 quarters · filed 2024-11-07 | $4.61M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $3.50M 10-Q · filed 2024-08-01 | |||
| 2023-03-31 | $2.23M 10-Q · filed 2024-05-08 | ||||
| 2022-09-30 | $829.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $1.57M derived: sum of 2 quarters · filed 2023-11-08 | $3.04M 10-Q · filed 2023-11-08 | ||
| 2022-06-30 | $746.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $2.21M 10-Q · filed 2023-08-02 | |||
| 2022-03-31 | $1.47M 10-Q · filed 2023-05-10 | ||||
| 2016-12-21 | $18.00M 10-K · filed 2017-03-13 | ||||
| 2014-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $1.81M derived: sum of 2 quarters · filed 2014-11-13 | $7.10M 10-Q · filed 2014-11-13 | ||
| 2014-09-17 | $37.50M 10-K · filed 2016-03-14 | ||||
| 2014-09-16 | $37.50M 10-Q · filed 2014-11-13 | ||||
| 2014-06-30 | $14.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $5.30M 10-Q · filed 2014-08-14 | |||
| 2014-03-31 | $5.29M 10-Q · filed 2014-05-15 | ||||
| 2013-08-16 | $8.20M 10-K · filed 2016-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |